Summary
Becton Dickinson & Co. (BDX) reported revenues of $4.25 billion for the three months ended March 31, 2020, a 1.4% increase year-over-year, primarily driven by volume growth, though this was partially offset by foreign currency translation impacts. The company experienced a net income of $183 million, or $0.53 per diluted share, a significant improvement from a net loss of $18 million in the prior year's comparable quarter. This improvement was largely due to a substantial reduction in "Other operating expense, net," which included significant charges in the prior year related to product liability matters and a business divestiture gain. The COVID-19 pandemic began to impact BDX's operations in the quarter, leading to an estimated $56 million unfavorable impact on consolidated revenues. While certain segments saw benefits, others, particularly those tied to elective medical procedures like the Interventional segment, experienced declines. Management has implemented cost containment measures and secured additional credit facilities to preserve financial flexibility amidst the evolving global economic conditions. Despite the external uncertainties, the company maintained a strong liquidity position.
Financial Highlights
52 data points| Revenue | $4.25B |
| Cost of Revenue | $2.52B |
| Gross Profit | $1.73B |
| R&D Expenses | $264.00M |
| SG&A Expenses | $1.02B |
| Operating Expenses | $3.88B |
| Operating Income | $370.00M |
| Interest Expense | $134.00M |
| Net Income | $183.00M |
| EPS (Basic) | $0.53 |
| EPS (Diluted) | $0.53 |
| Shares Outstanding (Basic) | 272.01M |
| Shares Outstanding (Diluted) | 275.04M |
Key Highlights
- 1Revenue increased by 1.4% to $4.25 billion for the quarter, driven by volume growth, though COVID-19 had an estimated unfavorable impact of $56 million.
- 2Net income improved significantly to $183 million ($0.53/share) from a net loss of $18 million ($0.07/share) in the prior year's quarter, largely due to the absence of significant prior-year charges.
- 3Operating cash flow for the first six months was $1.2 billion, demonstrating strong cash generation.
- 4The company reported substantial cash and short-term investments of $2.445 billion as of March 31, 2020, providing ample liquidity.
- 5BDX secured additional financing, including a $2.0 billion term loan and an increase in its revolving credit facility, to enhance financial flexibility amid COVID-19 uncertainties.
- 6The Medical segment saw revenue growth in Pharmaceutical Systems and Diabetes Care, but was impacted by delays in Alaris™ infusion pump shipments and COVID-19 related declines in other units.
- 7The Interventional segment experienced revenue growth but noted negative impacts from the deferral of elective medical procedures due to COVID-19.